Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting ( GENEVA Switzerland April 27 2007...)

HOME >> MEDICINE >> TECHNOLOGY

Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting

GENEVA, Switzerland, April 27, 2007 – Merck Serono S.A. (virt-x: SEO) and its partner Newron Pharmaceuticals S.p.A. (SWX: NWRN) announced today that Professor Fabrizio Stocchi, MD, PhD, will present the results of the first Phase III trial of safinamide as an adjunctive treatment to dopamine agonists (DA) in early Parkinson’s disease (PD) patients at the American Academy of Neurology 59th Annual Meeting to be held in Boston from 28 April to 5 May 2007.

The abstract entitled "Safinamide, a New Anti-Parkinson Agent is Effective and Well-Tolerated in Early PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-Controlled, Phase III Trial" was accepted for an oral presentation that is scheduled for Tuesday, May 1, 2007 at 3.45pm at Session S20: Movement Disorders: Essential Tremor and Medications for Parkinson’s Disease, at the Hynes Convention Center in Boston, MA, U.S.A.

Fabrizio Stocchi is a Professor of Neurology and Honorary Consultant at the IRCCS San Raffaele Rome, University "La Sapienza". He is Director of the Movement Disorders Centre and the Clinical Trial Center of the same institute.

In October 2006, Merck Serono and Newron signed a global development and commercialization agreement under which Newron has granted Merck Serono exclusive worldwide rights to develop, manufacture and commercialise safinamide in

Merck Serono 9 Chemin des Mines Corporate Media Relations Corporate Investor Relations 1202 Geneva Tel:+41 22 414 36 00 Tel:+41 22 414 36 01 Switzerland Media Relations, USA Investor Relations, USA www.merckserono.net Tel :+1 781 681 23 40 Tel:+1 781 681 25 52 News Release

Parkinson’s disease, Alzheimer’s disease, other cognitive disorders and Restless Leg Syndrome.

###
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
4. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
5. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:

(Date:3/17/2010)... Fourteenth Annual New York Emerging Growth Institutional Investor Forum at The Grand Hyatt in New York City on Tuesday, March 23, 2010 . , ... , , ... ... ...

(Date:3/17/2010)... Access MediQuip, LLC, the nation,s first and largest provider of outsourced implantable medical device management ... "RMS," for its customers nationwide. The new release is designed to protect patients, inform and ... ... ...

(Date:3/17/2010)... based on the,following elements: ,, ... , , ... ... "As former Vice-President for clinical drug development with a ...

Breaking Medicine Technology:Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum 2 Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices 2 Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices 3 Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities 2 Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities 3 Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities 4 American Laser Centers Names Health Care Veteran Steven Straus CEO 59137 1 American Laser Centers Names Health Care Veteran Steven Straus CEO 59137 2 Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools 14396 1 Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools 14396 2 Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 5333 1 Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 5333 2

[0] Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum [0] Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices [0] Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities

... the 90th annual Endocrine Society meeting show,significant improvements among women ... ... ANN ARBOR, Mich, June 16 QuatRx Pharmaceuticals today,announced detailed ... Ophena(TM) (ospemifene tablets) to treat postmenopausal women with,symptoms of vulvovaginal ...

... Results Presented at Endocrine Society 90th Annual Meeting ... 16 ,Bionovo Inc. (Nasdaq: BNVI ) today ... its drug candidate, MF101. The data were presented ... that, in neurons,differentiated from mouse stem cells and ...

Other Medicine Technology:Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 2 Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 3 Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 4 Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation 2 Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation 3

Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation

(Date:3/18/2010)... ... patients. The Plastic Surgery Institute of Southeast Texas provides their patients with a more suitable ... Houston, ... procedures. It is also one of the top concerns for people considering plastic surgery. TIVA, ...

(Date:3/18/2010)... , ... , ... ... WASHINGTON , March 18 Kids in Michigan will take center stage in the fight against tobacco on ...

(Date:3/18/2010)... Prevention Initiatives , ... , ... ... WASHINGTON , March 18 Kids in New Hampshire will take center stage in the ...

(Date:3/18/2010)... Initiatives , ... , ... ... WASHINGTON , March 18 Kids in Nebraska will take center stage in the fight against ...

(Date:3/18/2010)... March 18 A tasty, wholesome ... moms and kids can happily agree on. Simply…Go-Gurt is made ... of artificial colors, flavors and sweeteners. It is filled with ... milk containing both calcium and vitamin D. These convenient portable ...

[0] Plastic Surgery Institute of Southeast Texas Offers Milder Anesthesia for Outpatient Procedures [0] Michigan Kids 'Kick Butts' on March 24 [0] New Hampshire Kids 'Kick Butts' on March 24 [0] Nebraska Kids 'Kick Butts' on March 24 [0] New Simply...Go-Gurt Contains No High Fructose Corn Syrup, Artificial Flavors or Colors

... by 50%, study concludes, , , MONDAY, April 7 ... offer nutrition education and reward students for nutritious ... preventing childhood obesity, according to a Temple University ... multifaceted nutrition program reduced the number of overweight ...

... science education, scientific research, and the role science should play in ... ... NEW YORK, April 7, 2008 Since its launch in October,2006, the ... human health issues facing the 21st century, including the,brain, the human genome, ...

... Schizophrenia is a complex type of psychotic mental ... Huge gains in the effective treatment of individuals with ... of the first generation of antipsychotic drugs. The medications ... illness (delusions and hallucinations) and, to a lesser extent, ...

... SCRANTON, Pa., April 7, 2008 Penn Foster ... build essential skills,for working professionals. The program offerings ... -- Anatomy and Physiology, This broad ... working adults in,the health professions. Prospective nurses, medical ...

... is high in the antioxidant EGCG (epigallocatechin-3- gallate) which ... prematurely aged. Studies have suggested that the combination of ... providing protection against certain types of cancers, including breast ... University of Mississippi researchers now finds that consuming EGCG ...

... Enjoy His Young Family,and Active Life, MIDDLE ISLAND, ... Trade Center on September 11, 2001, New York,City Patrolman ... Now,more than seven years later, O,Connor needs help overcoming ... later in,the line of duty., At 32, Mr. ...

Other Medicine News:Health News:School Environment Can Curb Kids' Weight Gain 2 Health News:Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science' 2 Health News:Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science' 3 Health News:Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected 2 Health News:Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected 3 Health News:Penn Foster Career School Offers Certificate Programs 2 Health News:Ingredient found in green tea significantly inhibits breast cancer growth in female mice 2 Health News:The SCOOTER Store Donates Power Scooter to Former NYPD Officer Who Responded to 9/11 2 Health News:The SCOOTER Store Donates Power Scooter to Former NYPD Officer Who Responded to 9/11 3

School Environment Can Curb Kids' Weight Gain Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science'Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected Penn Foster Career School Offers Certificate Programs Ingredient found in green tea significantly inhibits breast cancer growth in female mice The SCOOTER Store Donates Power Scooter to Former NYPD Officer Who Responded to 9/11

... hip retractor system provides ... total hip replacement. Fully ... surgeon techniques on any ... Hand-held retractors can easily ...

... every general surgery need. No matter the ... GO550/GO500 Omni-Flex General Retractor Systems give you ... way possible., ,With large and small frame ... the GO550 provides comprehensive flexibility and completely ...

... The Arx Ceramic Spinal ... biocompatible implants based on ... that offers physicians and ... other synthetic and allograft ...

... QC 253 is an assayed quality ... of total hemoglobin and hemoglobin fractions on ... those needing a control that parallels the ... COHb. QC 253 is available in three ...

Medicine Products:

Omni-Flex Hip Retractor System GO550/GO500 Omni-Flex™ General Retractor Systems Arx™ Ceramic Spinal Spacer System™QC 253 Full Range CO-Oximeter Control

( GENEVA Switzerland April 27 2007...)Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting,Health